Literature DB >> 16955281

Nephrotoxicity with cyclooxygenase 2 inhibitor use in children.

Jeffery T Fletcher1, Nicole Graf, Anthony Scarman, Hamda Saleh, Stephen I Alexander.   

Abstract

The nephrotoxic potential of anti-inflammatory drugs alone and in compound preparations has been known for over fifty years. Nephrotoxicity associated with selective cyclooxygenase 2 (COX-2) inhibitor use is reported in adult patients but not in children. We present here the first report of reversible acute renal failure associated with the COX-2 inhibitor rofecoxib (Vioxx) in three children. Patient 1, an 18 month old girl with neonatal Bartter syndrome, developed acute renal failure with a peak creatinine of 1.9 mg/dl (164 micromol/l) and severe hyperkalemic metabolic acidosis. Patient 2, a 14 year old boy with a history of rheumatic fever, developed acute renal failure with a peak creatinine of 2.7 mg/dl (240 micromol/l). While patient 3, a healthy 14 year old girl, developed acute renal failure and tubulointerstitial nephritis confirmed on renal biopsy with a peak creatinine of 3.3 mg/dl (287 micromol/L). All children had been taking non-selective non-steroidal anti-inflammatory drugs (NSAID's) immediately prior to rofecoxib use. Renal function returned to normal within one week in all three patients and has remained normal at follow-up. This paper highlights the nephrotoxic risk of COX-2 inhibitor use in the pediatric population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16955281     DOI: 10.1007/s00467-006-0252-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

1.  Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.

Authors:  Nikolaus A Haas; Robert Nossal; Christoph H Schneider; Martin A G Lewin; Volker Ocker; Martin Holder; Frank Uhlemann
Journal:  Pediatr Crit Care Med       Date:  2003-04       Impact factor: 3.624

2.  Ibuprofen and acute renal failure in a toddler.

Authors:  N E Moghal; S Hegde; K M Eastham
Journal:  Arch Dis Child       Date:  2004-03       Impact factor: 3.791

3.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

Authors:  Nancy A Nussmeier; Andrew A Whelton; Mark T Brown; Richard M Langford; Andreas Hoeft; Joel L Parlow; Steven W Boyce; Kenneth M Verburg
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

4.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

6.  Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice.

Authors:  V F Norwood; S G Morham; O Smithies
Journal:  Kidney Int       Date:  2000-12       Impact factor: 10.612

7.  Acute renal dysfunction associated with selective COX-2 inhibitor therapy.

Authors:  D Papaioannides; C Bouropoulos; D Sinapides; P Korantzopoulos; N Akritidis
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 8.  Pediatric clinical trial experience: government, child, parent and physician's perspective.

Authors:  Juan C Salazar
Journal:  Pediatr Infect Dis J       Date:  2003-12       Impact factor: 2.129

9.  Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.

Authors:  Stephen J Kerr; Andrea Mant; Fiona E Horn; Kevin McGeechan; Geoffrey P Sayer
Journal:  Med J Aust       Date:  2003-10-20       Impact factor: 7.738

10.  Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.

Authors:  Stephan C Reinalter; Nikola Jeck; Christoph Brochhausen; Bernhard Watzer; Rolf M Nüsing; Hannsjörg W Seyberth; Martin Kömhoff
Journal:  Kidney Int       Date:  2002-07       Impact factor: 10.612

View more
  5 in total

Review 1.  Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Authors:  Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2022-09-02       Impact factor: 3.930

2.  Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies.

Authors:  Włodzimierz Matysiak; Barbara Jodłowska-Jedrych
Journal:  Protoplasma       Date:  2010-08-19       Impact factor: 3.356

3.  Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data.

Authors:  Deborah M Levy; Lisa F Imundo
Journal:  Pediatr Rheumatol Online J       Date:  2010-02-04       Impact factor: 3.054

4.  Late-onset Bartter syndrome type II.

Authors:  Benjamin Gollasch; Yoland-Marie Anistan; Sima Canaan-Kühl; Maik Gollasch
Journal:  Clin Kidney J       Date:  2017-05-08

Review 5.  Nephrotoxicity as a cause of acute kidney injury in children.

Authors:  Ludwig Patzer
Journal:  Pediatr Nephrol       Date:  2008-01-29       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.